No Data
No Data
It's Time for Investors to Rotate, With Opportunities Down the Market Cap – Piper Sandler
Canaccord Genuity Cuts Pliant to Hold on Study Setback
Pliant Therapeutics Downgraded to Neutral From Overweight at JPMorgan
A Quick Look at Today's Ratings for Pliant Therapeutics(PLRX.US), With a Forecast Between $4 to $32
Analysts Offer Insights on Healthcare Companies: Replimune Group (REPL), Pliant Therapeutics (PLRX) and Immunovant (IMVT)
12 Health Care Stocks Moving In Monday's Pre-Market Session
Unlock the Full List